PMID- 1467321
OWN - NLM
STAT- MEDLINE
DCOM- 19930127
LR  - 20120531
IS  - 0914-7470 (Print)
IS  - 0914-7470 (Linking)
VI  - 5
IP  - 3
DP  - 1992 Sep
TI  - Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer 
      cells and interleukin-2 in the adoptive immunotherapy of patients with 
      malignancies.
PG  - 226-35
AB  - Clinical effects and side effects were investigated in the adoptive immunotherapy 
      of patients bearing malignant diseases using human leukocyte antigen 
      (HLA)-mismatched allogeneic lymphokine-activated killer (LAK) cells. Allogeneic 
      LAK cells were induced from peripheral blood lymphocytes (PBL) of healthy donors 
      with the same blood types as those of patients. Recently we succeeded in 
      increasing the proliferation rate and enhancing the cytotoxic activity of LAK 
      cells by means of initial stimulation with pokeweed mitogen (PWM, PWM-LAK cells). 
      Five of 12 patients applied in the adoptive immunotherapy showed clinical effects 
      such as partial or complete regression of pulmonary metastases and pleural 
      effusion. All pulmonary metastatic lesions were eliminated in one case by this 
      adoptive immunotherapy combined with chemotherapy. Toxic effects were chillness, 
      fever and general fatigue which were reversible, and no allergic side effects 
      occurred even though allogeneic LAK cells were injected frequently. In the 
      patients who received more than 10(11) of allogeneic LAK cells, anti-HLA class I 
      antibodies appeared without any evidence of autoantibody. However, immunological 
      side effects were never experienced after injection of allogeneic LAK cells even 
      when the anti-HLA class I antibodies existed in the patients; this phenomenon 
      suggests the safety of the adoptive immunotherapy using allogeneic LAK cells. 
      Taken together, allogeneic LAK cells could be considered as alternative therapy 
      for patients with malignancies who could not supply sufficient materials of 
      autologous LAK cells. Recently, LAK cells, particularly PWM-LAK cells were found 
      to obtain significantly potent and prompt lectin-dependent cell-mediated 
      cytotoxicity (LDCC). All tumor cells confluent in microtest plate well could be 
      annihilated by PWM-LAK cells plus PWM less than 8 hours. New immunotherapy using 
      PWM-LAK cells or lectin-stimulated LAK cells with PWM or other lectins is 
      discussed.
FAU - Kimoto, Y
AU  - Kimoto Y
AD  - Department of Oncologic Surgery, Research Institute of Microbial Diseases, Osaka 
      University.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Hum Cell
JT  - Human cell
JID - 8912329
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Interleukin-2)
RN  - 0 (Pokeweed Mitogens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibody Formation
MH  - Cytotoxicity, Immunologic
MH  - Female
MH  - *HLA Antigens
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Immunity, Cellular
MH  - *Immunotherapy, Adoptive
MH  - Interleukin-2/therapeutic use
MH  - Killer Cells, Lymphokine-Activated/immunology/*transplantation
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/immunology/*therapy
MH  - Pokeweed Mitogens/pharmacology
EDAT- 1992/09/01 00:00
MHDA- 1992/09/01 00:01
CRDT- 1992/09/01 00:00
PHST- 1992/09/01 00:00 [pubmed]
PHST- 1992/09/01 00:01 [medline]
PHST- 1992/09/01 00:00 [entrez]
PST - ppublish
SO  - Hum Cell. 1992 Sep;5(3):226-35.